JCT  Vol.5 No.14 , December 2014
Possible Chemosensitizing and Potent Anticancer Effects of D-Fraction in Combination with Vitamin C on Three Prevalent Urologic Cancer Cells
Abstract: Chemotherapy is currently one of the most common therapeutic options for cancer patients despite the poor efficacy with considerable side effects. We then examined if D-fraction (DF), a bioactive mushroom extract, could potentiate (poor) anticancer effects of those drugs in vitro. Three urologic cancers, prostate, bladder, and kidney cancers, were tested with various chemotherapeutic drugs and their combinations with DF. Compared to individual drugs alone, combinations of drugs and DF have improved anticancer activity, resulting in the significant (P < 0.05) cell viability reduction in all three cancer cells. As vitamin C (VC) has been postulated to potentiate the bioactivity of DF, this possibility was also examined. The specific combination of DF (300 μg/ml) and VC (200 μM) indeed led to the drastic (≥90%) viability reductions in all three cancer cells. To have a better understanding of such a profound viability reduction, the effect of DF/VC combination on cell cycle was examined next. Cell cycle analysis indicated that this combination induced a G1cell cycle arrest, which was also confirmed by the down-regulation of specific cell cycle regulators (CDK2, CDK4, and cyclin D1) detected on western blots. Moreover, it was crucial to address if the DF/VC-induced viability reduction could be also linked to apoptosis. Western blot analysis revealed that anti-apoptotic bcl-2 was down-regulated while pro-apoptotic Bax was up-regulated with DF/VC combination in all cancer cells, indicating induction of apoptosis. Therefore, the DF/VC combination could ultimately induce apoptosis, accounting for the severe cell viability reduction. In conclusion, DF appears to be a promising agent with chemosensitizing effect, enhancing the efficacy of chemotherapeutic drugs, and its combination with VC exhibits a potent anticancer effect, which is far superior to any combinations of drugs and DF tested in three prevalent urologic cancer cells.
Cite this paper: Freilich, D. , Moskowitz, E. , Feuer, N. , Choudhury, M. , Phillips, J. and Konno, S. (2014) Possible Chemosensitizing and Potent Anticancer Effects of D-Fraction in Combination with Vitamin C on Three Prevalent Urologic Cancer Cells. Journal of Cancer Therapy, 5, 1402-1411. doi: 10.4236/jct.2014.514142.

[1]   Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009) Cancer Statistics 2009. CA: A Cancer Journal for Clinicians, 59, 225-249.

[2]   Mimeault, M., Mehta, P.P., Hauke, R., et al. (2007) Improvement of Cytotoxic Effects Induced by Mitoxantrone on Hormone-Refractory Metastatic Prostate Cancer Cells by Co-Targeting Epidermal Growth Factor Receptor and Hedgehog Signaling Cascades. Growth Factors, 25, 400-416.

[3]   Di Lorenzo, G. and De Placido, S. (2006) Hormone Refractory Prostate Cancer (HRPC): Present and Future Approaches of Therapy. International Journal of Immunopathology and Pharmacology, 19, 11-34.

[4]   Kamel, M.H., Moore, P.C., Bissada, N.K. and Heshmat, S.M. (2012) Potential Years of Life Lost Due to Urogenital Cancer in the United States: Trends from 1972 to 2006 Based on Data from the SEER Database. Journal of Urology, 187, 868-871.

[5]   Kaufman, D.S., Shipley, W.U. and Feldman, A.S. (2009) Bladder Cancer. Lancet, 374, 239-249.

[6]   Pow-Sang, J.M. and Seigne, J.D. (2000) Contemporary Management of Superficial Bladder Cancer. Cancer Control, 7, 335-339.

[7]   Jemal, A., Murray, T., Ward, E., et al. (2005) Cancer Statistics 2005. CA: A Cancer Journal for Clinicians, 55, 10-30.

[8]   Jacobsohn, K.M. and Wood, C.G. (2006) Adjuvant Therapy for Renal Cell Carcinoma. Seminars in Oncology, 33, 576-582.

[9]   Glaspy, J.A. (2002) Therapeutic Options in the Management of Renal Cell Carcinoma. Seminars in Oncology, 29, 41-46.

[10]   Jones, J., Juengel, E., Mickuckyte, A., et al. (2009) The Histone Deacetylase Inhibitor Valproic Acid Alters Growth Properties of Renal Cell Carcinoma in Vitro and in Vivo. Journal of Cellular and Molecular Medicine, 13, 2376-2385.

[11]   Garcia, J.A. and Danielpour, D. (2008) Mammalian Target of Rapamycin Inhibition as a Therapeutic Strategy in the Management of Urologic Malignancies. Molecular Cancer Therapeutics, 7, 1347-1354.

[12]   Inamoto, T. and Azuma, H. (2012) Immunotherapy of Genitourinary Malignancies. Journal of Oncology, 2012, 1-8.

[13]   Mizuno, T. and Zhuang, C. (1995) Maitake, Grifola frondosa: Pharmacological Effects. Food Reviews International, 11, 135-149.

[14]   Adachi, K., Nanba, H. and Kuroda, H. (1987) Potentiation of Host-Mediated Antitumor Activity in Mice by β-Glucan Obtained from Grifola frondosa (Maitake). Chemical and Pharmaceutical Bulletin (Tokyo), 35, 262-270.

[15]   Hishida, I., Nanba, H. and Kuroda, H. (1988) Antitumor Activity Exhibited by Orally Administered Extract from Fruit Body of Grifola frondosa (Maitake). Chemical and Pharmaceutical Bulletin (Tokyo), 36, 1819-1827.

[16]   Suzuki, I., Hashimoto, K., Oikawa, S., Sato, K., Osawa, M. and Yadomae, T. (1989) Antitumor and Immunomodulating Activities of a Beta-Glucan Obtained from Liquid-Cultured Grifola frondosa. Chemical and Pharmaceutical Bulletin (Tokyo), 37, 410-413.

[17]   Pyo, P., Louie, B., Rajamahanty, S., Choudhury, M. and Konno, S. (2008) Possible Immunotherapeutic Potentiation with D-Fraction in Prostate Cancer Cells. Journal of Hematology and Oncology, 1, 25-33.

[18]   Morishige, F. (1986) The Role of Vitamin C in Tumor Therapy (Human). In: Meyskens Jr., F.I. and Parasad, K.N., Eds., Vitamins and Cancer: Human Cancer Prevention by Vitamins and Micronutrients, Humana Press, Clifton, 399-427.

[19]   Mordente, J.A., Konno, S., Chen, Y., Wu, J.M., Tazaki, H. and Mallouh, C. (1998) The Effects of Brefeldin A (BFA) on Cell Cycle Progression Involving the Modulation of the Retinoblastoma Protein (pRB) in PC-3 Prostate Cancer Cells. Journal of Urology, 159, 275-279.

[20]   Ullah, M.F., Bhat, S.H., Hussain, E., Abu-Duhier, F., Ahmad, A. and Hadi, S.M. (2012) Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy. Current Drug Targets, 13, 1757-1771.

[21]   Chen, Q., Espey, M.G., Krishna, M.C., Mitchell, J.B., Corpe, C.P., Buettner, G.R., et al. (2005) Pharmacologic Ascorbic Acid Concentrations Selectively Kill Cancer Cells: Action as a Pro-Drug to Deliver Hydrogen Peroxide to Tissues. Proceedings of the National Academy of Sciences of the United States of America, 102, 13604-13609.

[22]   Sherr, C.J. (2000) The Pezcoller Lecture: Cancer Cell Cycle Revisited. Cancer Research, 60, 3689-3695.

[23]   Yip, K.W. and Reed, J.C. (2008) Bcl-2 Family Proteins and Cancer. Oncogene, 27, 6398-6406.

[24]   Maitake Products, Inc. (1998) D-Fraction Obtained IND for Clinical Study. Corporate Publication, Paramus.